The GI Cancer Institute has been changing outcomes for people with gastro-intestinal (GI) cancer since 1991. The Spencer Gibson Foundation has provided partial funding to support research concepts and pilot studies to achieve better health outcomes for patients with gastro-intestinal cancers.
gicancer.org.au
| 2017 | Reno |
| A study to assess the safety of the watch and wait approach to surgery for locally advanced rectal cancer following chemotherapy and radiotherapy. | |
| Principal Investigator Professor Chris Karapetis | |
| 2018 | Oxtox |
| Research to reduce the side effects of acute neuropathy caused by chemotherapy for metastatic colorectal cancer. | |
| Principal Investigator Professor Janette Vardy | |
| 2019 | Forecast One |
| A study to be conducted on patient derived tumour organoids to identify which treatments are effective for individual patients with refractory metastatic colorectal cancer. | |
| Principal Investigator Professor Peter Gibbs | |
| 2020 | Neo-Impact |
| Pilot study investigating if treating pancreatic cancer patients with immunotherapy before surgery could result in better responses to treatment and in turn improved survival outcomes. | |
| Principal Investigator Dr Lorraine Chantrill | |
| 2020 | GI Cancer Innovation Grant |
| The Spencer Gibson Foundation supported the GI Cancer Innovation Grant which awarded funds to a study in colorectal cancer and two sub studies in pancreatic cancer and neuroendocrine cancer, furthering medical knowledge to improve outcomes and giving hope to people diagnosed with GI cancers. | |
| 2021 | Clinical Trials |
| The Spencer Gibson Foundation supported the GI Cancer Institute to undertake clinical trial oversight for government funded trials—Topgear, Paleo and Neo-Create for patients with gastric, oesophageal or gastro-oesophageal cancers. |
Read next: Other Grant recipients »